Primary hypercholesterolaemia/mixed dyslipidaemia
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

REPATHA®
DELIVERS
CONSISTENT,
INTENSIVE LDL-C
LOWERING1

Repatha® for LDL-C lowering

  • Up to 75% LDL-C reduction vs placebo at the mean of weeks 10 and 12 for every 2-week and monthly regimen2
  • 88–94% of patients achieved LDL-C <70 mg/dl (<1.8 mmol/l) at the mean of Weeks 10 and 122
  • LDL-C reductions were similar in all patients regardless of age, race, baseline LDL-C, BMI, CV risk, or presence of diabetes or hypertension2

Mean LDL-C percent change from baseline to mean of Weeks 10 and 12*2

LAPLACE-2 was an international, multicentre, double-blind, randomised, 12-week study in 1896 patients with primary hypercholesterolaemia or mixed dyslipidaemia who were randomised to receive Repatha® in combination with statins (rosuvastatin, simvastatin or atorvastatin). Repatha® was compared to placebo for the rosuvastatin and simvastatin groups and compared with placebo and ezetimibe for the atorvastatin group.*2

*Co-primary endpoints were mean percent change from baseline in LDL‐C at the mean of Weeks 10 and 12 and at Week 12 alone. Mean LDL-C achieved for patients receiving Repatha® was 33 mg/dl (0.85 mmol/l) to 49 mg/dl (1.27 mmol/l). Secondary endpoints included the mean at weeks 10 and 12 and at week 12 for the change from baseline in LDL-C levels.
In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; BMI = Body mass index; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; LAPLACE = LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; Q2W = Every 2 weeks; QD = Every day; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
  2. Robinson JG, et al. JAMA. 2014;311:1870-82.
  3. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD